Kommentar zu „Herzinsuffizienz und Übergewicht: Semaglutid verbessert kardiovaskuläre Funktion“

• Literatur

• 1 McDonagh TA, Metra M, Adamo M. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44 (37) 3627-3639
• 2 Borlaug BA, Jensen MD, Kitzman DW. et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118 (18) 3434-3450
• 3 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375 (19) 1834-1844
• 4 Wilding JPH, Batterham RL, Calanna S. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384 (11) 989-1002
• 5 Spertus JA, Jones PG, Sandhu AT. et al. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 76 (20) 2379-2390
• 6 Borlaug BA, Kitzman DW, Davies MJ. et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med 2023; 29 (09) 2358-2365
• 7 Lincoff AM, Brown-Frandsen K, Colhoun HM. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389 (24) 2221-2232
• 8 Lingvay I, Brown-Frandsen K, Colhoun HM. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring) 2023; 31 (01) 111-122